Forest sues would-be Savella copycats; U.K. health service rolls out Roche's sub-Q Herceptin;

@FiercePharma: Lundbeck's refusal to sell pentobarbital to prisons hits Ohio's execution plans. More from Reuters | Follow @FiercePharma

@EricPFierce: FDA warning letter for Strides Arcolab Agila Speciaities plant arrives. Mylan not too concerned. Story from FiercePharmaManufacturing | Follow @EricPFierce

> Forest Laboratories ($FRX) sued several generics makers for patent infringement over their plans to knock off the fibromyalgia drug Savella. Release

> The U.K.'s National Health Service adopted Roche's ($RHHBY) new injectable form of the HER2-positive breast cancer drug Herceptin. Report

> Par Pharmaceutical started shipping the new antidepressant Khedezla ER, a copycat version of Pfizer's ($PFE) Pristiq that isn't generically substitutable for the brand. Report

> Purdue Pharma won FDA approval for a new dosage strength of its Butrans Transdermal painkiller patch. Report

Medical Device News

@FierceMedDev: Biocept Laboratories becomes latest Dx outfit to explore IPO. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Medtronic won expanded indications for one of its key vascular stents. Release | Article | Follow @MarkHFierce

> Stryker inks $1.7B deal for Mako. News

> Tool to predict bad implant reactions shows potential. Item

> EnteroMedics slides after FDA squints at obesity device. Article

Biotech News

@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | FierceBiotech's 2013 Fierce 15 | Follow @FierceBiotech

@JohnCFierce: Merck KGaA doubles down on Oncothyreon's failed cancer vaccine. Report | Follow @JohnCFierce

@DamianFierce: Apparently no one wanted to spend ~$3B on Clovis Oncology. Perhaps Big Pharma wants its biotechs to generate revenue. Story | Follow @DamianFierce

@EmilyMFierce: Stem cell reprogramming made easier by removing one protein. Popular yesterday from FierceBiotech Research | Follow @EmilyMFierce

> Infinity dumps lung cancer drug after PhII trial fails survival test. Article

> Plotting Asia expansion, Amgen blueprints plans for Shanghai research center. More

> Ophthotech, Foundation Medicine loot booming biotech IPO market for $273M. Article

Drug Delivery News

@MichaelGFierce: Laser-sensitive surface enables IV-drug identification for safer delivery. Story | Follow @MichaelGFierce

> Study: Artificial pancreas with inhaled insulin improves glucose control. More

> Alnylam heralds positive results for RNAi amyloidosis drug. Article

> Surefire collects $16.4M to expand cancer-drug catheter biz. Item

> Bind collects $70.5M IPO to support Accurin tech. Story

Diagnostics News

> Cognoptix Alzheimer's eye test generates robust trial results. Article

> Alzheimer's diagnosis may gain from PET imaging of tau proteins. Report

> Case Western, GSK find promise with MS diagnostic 'probe.' Story

> In vitro Dx to remain at top of med tech heap. More

> Cigna: Genetic counseling mandates will come for other Dx tests. Article

And Finally... The new federal health law is expected to cause a surge in patients seeking mental healtlh treatment. Report

Suggested Articles

If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.

Eylea sales dropped 4% to $1.11 billion amid the pandemic, but still beat expectations. And meanwhile, Regeneron's COVID antibody is advancing.

Johnson & Johnson inked a $10-per-dose vaccine supply deal with the U.S. for 100 million initial doses, with 200 million more available down the line.